Log in

Relevant bibliographies by topics / 6-Thioguanin / Journal articles

To see the other types of publications on this topic, follow the link: 6-Thioguanin.

Journal articles on the topic '6-Thioguanin'

Author: Grafiati

Published: 4 June 2021

Last updated: 18 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic '6-Thioguanin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Klugmann, T., and B. Bokemeyer. "Langzeit-Verträglichkeit der 6-Thioguanin- Therapie bei CED-Patienten in der gastroenterologischen Fachpraxis." Verdauungskrankheiten 23, no. 07 (2005): 181–85. http://dx.doi.org/10.5414/vdp23181.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Haas, R., A. Mundinger, T. Bohn, K. Schaz, and W. Hunstein. "Therapiemöglichkeiten beim Hypereosinophilie-Syndrom mit Endomyocarditis fibroplastica Löffler: Wirksamkeit von Cytarabin und 6-Thioguanin." DMW - Deutsche Medizinische Wochenschrift 110, no. 41 (2008): 1573–76. http://dx.doi.org/10.1055/s-2008-1069049.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Abrahamsson, Jonas, Erik Forestier, Jesper Heldrup, et al. "Response-Guided Induction Therapy in Pediatric Acute Myeloid Leukemia With Excellent Remission Rate." Journal of Clinical Oncology 29, no. 3 (2011): 310–15. http://dx.doi.org/10.1200/jco.2010.30.6829.

Full text

Abstract:

Purpose To evaluate the early treatment response in children with acute myeloid leukemia (AML) using a response-guided induction strategy that includes idarubicin in the first course. Patients and Methods All Nordic children with AML younger than 15 years (n = 151) were treated on the Nordic Society for Pediatric Hematology and Oncology (NOPHO) AML 2004 protocol. After the first course of idarubicin, cytarabine, etoposide, and 6-thioguanin, patients with good response were allowed hematologic recovery before the second course, whereas patients with a poor (≥ 15% blasts) or intermediate (5% to

APA, Harvard, Vancouver, ISO, and other styles

4

Herrlinger, Klaus R., Matthias Schwab, Klaus Fellermann, and Eduard F. Stange. "6-thioguanine-buried alive?" Gastroenterology 126, no. 3 (2004): 940–41. http://dx.doi.org/10.1053/j.gastro.2004.01.044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Feistner, Gottfried, and Carle M. Staub. "6-Thioguanine fromErwinia amylovora." Current Microbiology 13, no. 2 (1986): 95–101. http://dx.doi.org/10.1007/bf01568289.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Josting, Andreas, Sabine Wiedenmann, Jeremy Franklin, et al. "Secondary Myeloid Leukemia and Myelodysplastic Syndromes in Patients Treated for Hodgkin’s Disease: A Report From the German Hodgkin’s Lymphoma Study Group." Journal of Clinical Oncology 21, no. 18 (2003): 3440–46. http://dx.doi.org/10.1200/jco.2003.07.160.

Full text

Abstract:

Purpose: To assess the incidence and outcome of secondary acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in patients with Hodgkin’s disease (HD). Patients and Methods: Between 1981 and 1998, the GHSG conducted three trial generations for early, intermediate, and advanced HD involving a total of 5,411 patients (called HD1 through HD9). Results: A total of 46 patients with secondary AML/MDS were identified. The median age at diagnosis of leukemia was 47 years (range, 22 to 79 years). Primary therapy was as follows: radiotherapy alone (n = 4); doxorubicin, bleomycin, vinblastine,

APA, Harvard, Vancouver, ISO, and other styles

7

Kraske, P. J., and Brajter-Toth. "Electrochemical oxidation of 6-thioguanine." Journal of Electroanalytical Chemistry and Interfacial Electrochemistry 207, no. 1-2 (1986): 101–16. http://dx.doi.org/10.1016/0022-0728(86)87065-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Sherer, Daniel W., and Mark G. Lebwohl. "6-Thioguanine in the Treatment of Psoriasis: A Case Report and Literature Review." Journal of Cutaneous Medicine and Surgery 6, no. 6 (2002): 546–50. http://dx.doi.org/10.1177/120347540200600605.

Full text

Abstract:

Background: 6-Thioguanine is a purine analog primarily indicated for acute myelogenous leukemia. Its use in psoriasis was first investigated in the 1950s and current interest in serious treatments for psoriasis, such as cyclosporine, has renewed interest in this medication. Newer therapies, such as PUVA and retinoids, have side effects as do some older treatments, such as methotrexate, which fell into favor at the same time 6-thioguanine was being investigated. Reexamining older treatments can open up new therapeutic options in difficult cases. Objective: The goal of this article is to provide

APA, Harvard, Vancouver, ISO, and other styles

9

Wensing, A., M. Gernold, S. Jock, et al. "6-THIOGUANINE BIOSYNTHESIS IN ERWINIA SPECIES." Acta Horticulturae, no. 1056 (October 2014): 165–67. http://dx.doi.org/10.17660/actahortic.2014.1056.25.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Siouri, Faady M., Samuel Boldissar, Jacob A. Berenbeim, and Mattanjah S. de Vries. "Excited State Dynamics of 6-Thioguanine." Journal of Physical Chemistry A 121, no. 28 (2017): 5257–66. http://dx.doi.org/10.1021/acs.jpca.7b03036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Manikowski, Andrzej, and Jerzy Boryski. "Transglycosylation Reactions of 6-Thioguanine Acyclonucleosides." Nucleosides, Nucleotides and Nucleic Acids 19, no. 10-12 (2000): 1569–80. http://dx.doi.org/10.1080/15257770008045447.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Zackheim, Herschel S., and Howard I. Maibach. "TREATMENT OF PSORIASIS WITH 6-THIOGUANINE." Australasian Journal of Dermatology 29, no. 3 (1988): 163–67. http://dx.doi.org/10.1111/j.1440-0960.1988.tb00391.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Ono, Akira, Takahiro Atsugi, Misato Goto, et al. "Crystal structure of a DNA duplex cross-linked by 6-thioguanine–6-thioguanine disulfides: reversible formation and cleavage catalyzed by Cu(ii) ions and glutathione." RSC Advances 9, no. 40 (2019): 22859–62. http://dx.doi.org/10.1039/c9ra03515j.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Kretz, K. A., J. R. Katze, and R. W. Trewyn. "Guanine analog-induced differentiation of human promyelocytic leukemia cells and changes in queuine modification of tRNA." Molecular and Cellular Biology 7, no. 10 (1987): 3613–19. http://dx.doi.org/10.1128/mcb.7.10.3613.

Full text

Abstract:

Treatment of hypoxanthine-guanine phosphoribosyltransferase (HGPRT)-deficient human promyelocytic leukemia (HL-60) cells with 6-thioguanine results in growth inhibition and cell differentiation. 6-Thioguanine is a substrate for the tRNA modification enzyme tRNA-guanine ribosyltransferase, which normally catalyzes the exchange of queuine for guanine in position 1 of the anticodon of tRNAs for asparagine, aspartic acid, histidine, and tyrosine. During the early stages of HGPRT-deficient HL-60 cell differentiation induced by 6-thioguanine, there was a transient decrease in the queuine content of

APA, Harvard, Vancouver, ISO, and other styles

15

Kretz, K. A., J. R. Katze, and R. W. Trewyn. "Guanine analog-induced differentiation of human promyelocytic leukemia cells and changes in queuine modification of tRNA." Molecular and Cellular Biology 7, no. 10 (1987): 3613–19. http://dx.doi.org/10.1128/mcb.7.10.3613-3619.1987.

Full text

Abstract:

Treatment of hypoxanthine-guanine phosphoribosyltransferase (HGPRT)-deficient human promyelocytic leukemia (HL-60) cells with 6-thioguanine results in growth inhibition and cell differentiation. 6-Thioguanine is a substrate for the tRNA modification enzyme tRNA-guanine ribosyltransferase, which normally catalyzes the exchange of queuine for guanine in position 1 of the anticodon of tRNAs for asparagine, aspartic acid, histidine, and tyrosine. During the early stages of HGPRT-deficient HL-60 cell differentiation induced by 6-thioguanine, there was a transient decrease in the queuine content of

APA, Harvard, Vancouver, ISO, and other styles

16

Leszczynski, Jerzy. "Tautomers of 6-thioguanine: structures and properties." Journal of Physical Chemistry 97, no. 14 (1993): 3520–24. http://dx.doi.org/10.1021/j100116a014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

LeLeiko, Neal S., Debra Lobato, Sarah Hagin, et al. "6-Thioguanine Levels in Pediatric IBD Patients." Inflammatory Bowel Diseases 19, no. 12 (2013): 2652–58. http://dx.doi.org/10.1097/01.mib.0000436960.00405.56.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Larrey, D., E. Freneaux, A. Berson, et al. "Peliosis hepatis induced by 6-thioguanine administration." Gut 29, no. 9 (1988): 1265–69. http://dx.doi.org/10.1136/gut.29.9.1265.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Singh, Kamalendra, R. A. Yadav, and J. S. Yadav. "Vibrational studies of biomolecules—III. 6-Thioguanine." Spectrochimica Acta Part A: Molecular Spectroscopy 47, no. 6 (1991): 819–20. http://dx.doi.org/10.1016/0584-8539(91)80154-b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Barek, Jiří, Antonín Berka, Ludmila Dempírová, and Jiří Zima. "Polarographic and voltammetric determination of 6-mercaptopurine and 6-thioguanine." Collection of Czechoslovak Chemical Communications 51, no. 11 (1986): 2466–72. http://dx.doi.org/10.1135/cccc19862466.

Full text

Abstract:

Conditions were found for the determination of 6-mercaptopurine (I) and 6-thioguanine (II) by TAST polarography, differential pulse polarography and fast-scan differential pulse voltammetry at a hanging mercury drop electrode. The detection limits were 10-6, 8 . 10-8, and 6 . 10-8 mol l-1, respectively. A further lowering of the detection limit to 2 . 10-8 mol l-1 was attained by preliminary accumulation of the determined substances at the surface of a hanging mercury drop.

APA, Harvard, Vancouver, ISO, and other styles

21

Santhosh, C., and P. C. Mishra. "Electronic structures and spectra of 6-mercaptopurine and 6-thioguanine." Spectrochimica Acta Part A: Molecular Spectroscopy 49, no. 7 (1993): 985–93. http://dx.doi.org/10.1016/0584-8539(93)80217-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Bronk, J. R., Norma Lister, and M. I. Shaw. "Transport and metabolism of 6-thioguanine and 6-mercaptopurine in mouse small intestine." Clinical Science 74, no. 6 (1988): 629–38. http://dx.doi.org/10.1042/cs0740629.

Full text

Abstract:

1. The transport of 6-thioguanine and 6-mercaptopurine has been studied with isolated jejunal loops of mouse small intestine. H.p.l.c. was used to identify and quantify the thiopurines and their metabolites in the serosal secretions. 2. When the lumen of the intestinal loops contained either 6-thioguanine or 6-mercaptopurine at a concentration of 1 mmol/l, the concentration of unmetabolized drug in the serosal secretions reached a maximum of 0.13 ± 0.02 mmol/l (mean ± sem). 3. Analysis of the serosal secretions from the perfusions with either of the drugs revealed the appearance of an unknown

APA, Harvard, Vancouver, ISO, and other styles

23

Jharap, B., NKH de Boer, RM Vos, et al. "Biotransformation of 6-thioguanine in inflammatory bowel disease patients: a comparison of oral and intravenous administration of 6-thioguanine." British Journal of Pharmacology 163, no. 4 (2011): 722–31. http://dx.doi.org/10.1111/j.1476-5381.2011.01265.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Kröplin, T., and H. Iven. "Methylation of 6-mercaptopurine and 6-thioguanine by thiopurine S -methyltransferase." European Journal of Clinical Pharmacology 56, no. 4 (2000): 343–45. http://dx.doi.org/10.1007/s002280000137.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Ren, Hong Jiang. "Theoretical Investigation on Tautomerization Mechanism of 6-Thioguanine." Advanced Materials Research 690-693 (May 2013): 1418–21. http://dx.doi.org/10.4028/www.scientific.net/amr.690-693.1418.

Full text

Abstract:

The tautomerization reaction mechanisms between three stable 6-thioguanine tautomers were investigated theoretically using B3LYP/6-311+G(d,p) method. The results show that the pathway P(1) is to isomerize from TG(9,10,10,11) to TG(1,9,10,10) and the needed activation Gibbs free energy barrier is 112.7 kJ/mol with the rate constant of 1.12×10-7 s-1. Another two pathways P(2) and P(3) are to isomerize from TG(1,9,10,10) to TG(1,7,10,10) and the activation Gibbs free energy barriers of the rate-determining steps are 227.4 and 281.6 kJ/mol, respectively, with the related rate constants of 8.96×10-

APA, Harvard, Vancouver, ISO, and other styles

26

Kim, Jae Ho, Alan A. Alfieri, Sang Hie Kim, and Seung S. Hong. "Radiosensitization of two murine fibrosarcomas with 6-thioguanine." International Journal of Radiation Oncology*Biology*Physics 18, no. 3 (1990): 583–86. http://dx.doi.org/10.1016/0360-3016(90)90064-q.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

van den Brand, F. F., Y. S. de Boer, B. J. Verwer, et al. "Evaluation of 6-thioguanine therapy in autoimmune hepatitis." Journal of Hepatology 66, no. 1 (2017): S353—S354. http://dx.doi.org/10.1016/s0168-8278(17)31044-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Manikowski, Andrzej, and Jerzy Boryski. "ChemInform Abstract: Transglycosylation Reactions of 6-Thioguanine Acyclonucleosides." ChemInform 33, no. 20 (2010): no. http://dx.doi.org/10.1002/chin.200220184.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Tomsons, U. A., A. A. Avots, and I. A. Kolesnikova. "Optimization of the technology of 6-thioguanine production." Pharmaceutical Chemistry Journal 19, no. 2 (1985): 136–38. http://dx.doi.org/10.1007/bf00771781.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Norman, Amos, J. Cameron Mitchell, and Keisuke S. Iwamoto. "A sensitive assay for 6-thioguanine-resistant lymphocytes." Mutation Research Letters 208, no. 1 (1988): 17–19. http://dx.doi.org/10.1016/0165-7992(88)90014-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Lancaster, D. L., N. Patel, L. Lennard, and J. S. Lilleyman. "6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations." British Journal of Clinical Pharmacology 51, no. 6 (2001): 531–39. http://dx.doi.org/10.1046/j.0306-5251.2001.01391.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Gilissen, L. P. L., L. J. J. Derijks, A. Driessen, et al. "Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine." Digestive and Liver Disease 39, no. 2 (2007): 156–59. http://dx.doi.org/10.1016/j.dld.2006.10.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

LaDuke, Kathleen E., Sarah Ehling, John M. Cullen, and Wolfgang Bäumer. "Effects of azathioprine, 6-mercaptopurine, and 6-thioguanine on canine primary hepatocytes." American Journal of Veterinary Research 76, no. 7 (2015): 649–55. http://dx.doi.org/10.2460/ajvr.76.7.649.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Mitra, Raja, and Ashoka G. Samuelson. "Mitigating UVA light induced reactivity of 6-thioguanine through formation of a Ru(ii) half-sandwich complex." RSC Adv. 4, no. 46 (2014): 24304–6. http://dx.doi.org/10.1039/c4ra02960g.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Zackheim, Herschel S., Richard G. Glogau, David A. Fisher, and Howard I. Maibach. "6-Thioguanine treatment of psoriasis: Experience in 81 patients." Journal of the American Academy of Dermatology 30, no. 3 (1994): 452–58. http://dx.doi.org/10.1016/s0190-9622(94)70055-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Iven, H., S. Gutsche, and T. Wagner. "Uptake and metabolism of 6-thioguanine in human erythrocytes." Clinical Biochemistry 30, no. 3 (1997): 261. http://dx.doi.org/10.1016/s0009-9120(97)87708-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Herrlinger, Klaus R., Wolfgang Kreisel, Peter Deibert, Matthias Schwab, Klaus Fellermann, and Eduard F. Stange. "6-Thioguanine maintains remission in chronic active Crohn's disease." Gastroenterology 124, no. 4 (2003): A519. http://dx.doi.org/10.1016/s0016-5085(03)82624-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

LESZCZYNSKI, J. "ChemInform Abstract: Tautomers of 6-Thioguanine: Structures and Properties." ChemInform 24, no. 30 (2010): no. http://dx.doi.org/10.1002/chin.199330045.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Arias, Zoraida González, Jesús Luis Muñiz Álvarez, and Juan Miguel López Fonseca. "Surface Layers of 6-Thioguanine on the Mercury Electrode." Journal of Colloid and Interface Science 250, no. 2 (2002): 295–302. http://dx.doi.org/10.1006/jcis.2002.8339.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Gunasekaran, S., S. Kumaresan, R. Arunbalaji, G. Anand, S. Seshadri, and S. Muthu. "Vibrational assignments and electronic structure calculations for 6-thioguanine." Journal of Raman Spectroscopy 40, no. 11 (2009): 1675–81. http://dx.doi.org/10.1002/jrs.2318.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Rulyak, Stephen J., Michael D. Saunders, and Scott D. Lee. "Hepatotoxicity Associated With 6-Thioguanine Therapy for Crohn's Disease." Journal of Clinical Gastroenterology 36, no. 3 (2003): 234–37. http://dx.doi.org/10.1097/00004836-200303000-00010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Presta, M., M. Belleri, A. Vacca, and D. Ribatti. "Anti-angiogenic activity of the purine analog 6-thioguanine." Leukemia 16, no. 8 (2002): 1490–99. http://dx.doi.org/10.1038/sj.leu.2402646.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Rappaport, Harry P. "The 6-thioguanine/5-methyl-2-pyrimidinone base pair." Nucleic Acids Research 16, no. 15 (1988): 7253–67. http://dx.doi.org/10.1093/nar/16.15.7253.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Schouten, Teunis J., Ronney A. De Abreu, Egbert D. A. M. Schretlen, Marinella B. van Leeuwen, John M. van Baal, and Gérard A. M. de Vaan. "6-Thioguanine: High-dose 2-H infusions in goats." Journal of Cancer Research and Clinical Oncology 110, no. 2 (1985): 115–18. http://dx.doi.org/10.1007/bf00402722.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Eriksson, L., H. Amnéus, and J. Grawé. "Flow sorting and cloning of 6-thioguanine-resistant cells." Mutation Research/Environmental Mutagenesis and Related Subjects 216, no. 1 (1989): 86–88. http://dx.doi.org/10.1016/0165-1161(89)90038-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Contreras, J. Guillermo, and Joel B. Alderete. "AM1 studies on the prototropic tautomerism of 6-thioguanine." Journal of Molecular Structure: THEOCHEM 283 (July 1993): 283–87. http://dx.doi.org/10.1016/0166-1280(93)87139-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Ahluwalia, Vinod Kumar, Jasjeet Kaur, Balbir Singh Ahuja, and Gurvinder Singh Sodhi. "Thermal studies on organomercury(II) complexes of 6-thioguanine." Thermochimica Acta 176 (March 1991): 321–25. http://dx.doi.org/10.1016/0040-6031(91)80287-s.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Bayoumy, Ahmed B., Chris J. J. Mulder, Aathavan Loganayagam, et al. "Relationship Between Thiopurine S-Methyltransferase Genotype/Phenotype and 6-Thioguanine Nucleotide Levels in 316 Patients With Inflammatory Bowel Disease on 6-Thioguanine." Therapeutic Drug Monitoring 43, no. 5 (2021): 617–23. http://dx.doi.org/10.1097/ftd.0000000000000869.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Volonté, C., A. Rukenstein, D. M. Loeb, and L. A. Greene. "Differential inhibition of nerve growth factor responses by purine analogues: correlation with inhibition of a nerve growth factor-activated protein kinase." Journal of Cell Biology 109, no. 5 (1989): 2395–403. http://dx.doi.org/10.1083/jcb.109.5.2395.

Full text

Abstract:

Purine analogues were used in this study to dissect specific steps in the mechanism of action of nerve growth factor (NGF). Protein kinase N (PKN) is an NGF-activated serine protein kinase that is active in the presence of Mn++. The activity of PKN was inhibited in vitro by purine analogues, the most effective of which was 6-thioguanine (apparent Ki = 6 microM). Several different criteria indicated that 6-thioguanine is not a general inhibitor of protein kinases and that it is relatively specific for PKN. For instance, it did not affect protein kinases A or C and was without effect on the over

APA, Harvard, Vancouver, ISO, and other styles

50

Petit, Elise, Sophie Langouet, Hanane Akhdar, Christophe Nicolas-Nicolaz, André Guillouzo, and Fabrice Morel. "Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes." Toxicology in Vitro 22, no. 3 (2008): 632–42. http://dx.doi.org/10.1016/j.tiv.2007.12.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!